Vir Biotechnology (NASDAQ:VIR) EVP Verneuil Vanina De Sells 1,343 Shares of Stock

Vir Biotechnology, Inc. (NASDAQ:VIR) EVP Vanina de Verneuil sold 1,343 shares of the stock in a transaction that occurred on Monday, November 2nd. The shares were sold at an average price of $11.33, for a total transaction of $15,216.19. Following the transaction, the executive vice president owned 112,600 shares in the company, valued at approximately $1,275,758. This trade represents a 1.18% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Verneuil Vanina De also recently made the following trade(s):

• On Tuesday, November 3rd, Vanina de Verneuil sold 2,407 shares of Vir Biotechnology stock. The stock was sold at an average price of $11.10, for a total transaction of $26,717.70.

Vir Biotechnology Trading Up 4.9%

Shares of VIR opened at $11.77 on Thursday. The firm has a fifty day simple moving average of $11.02 and a two-hundred day simple moving average of $9.56. The firm has a market cap of $1.99 billion, a PE ratio of -6.33 and a beta of 1.70. Vir Biotechnology, Inc. has a 1-year low of $4.82 and a 1-year high of $12.19.

Vir Biotechnology (NASDAQ:VIR) last released its quarterly earnings results on Wednesday, November 4th. The company reported ($0.57) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.18. The firm had revenue of ($0.19) million during the quarter, compared to analysts’ expectations of $0.98 million. The business’s quarterly revenue was down 178.3% on a year-over-year basis. During the same quarter last year, the business earned ($1.17) earnings per share. As a group, research analysts forecast that Vir Biotechnology, Inc. will post -1.84 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. ADAR1 Capital Management LLC bought a new stake in shares of Vir Biotechnology during the 2nd quarter valued at $25,034,000. Parkman Healthcare Partners LLC purchased a new stake in shares of Vir Biotechnology in the 2nd quarter worth $4,843,000. ARCH Venture Management LLC purchased a new stake in shares of Vir Biotechnology in the 2nd quarter worth $129,353,521. Candriam S.C.A. raised its holdings in Vir Biotechnology by 10.1% in the 1st quarter. Candriam S.C.A. now owns 1,135,763 shares of the company’s stock worth $10,176,000 after purchasing an additional 104,100 shares during the period. Finally, BlackRock Inc. bought a new position in Vir Biotechnology in the 2nd quarter worth $210,712,000. Hedge funds and other institutional investors own 65.32% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have weighed in on VIR shares. HC Wainwright increased their target price on Vir Biotechnology from $20.00 to $22.00 and gave the company a “buy” rating in a report on Wednesday, October 7th. Raymond James Financial restated a “strong-buy” rating on shares of Vir Biotechnology in a research note on Monday, September 28th. Zacks Research downgraded Vir Biotechnology from a “hold” rating to a “strong sell” rating in a research note on Tuesday, October 6th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vir Biotechnology in a research report on Friday, October 2nd. Finally, Wall Street Zen upgraded shares of Vir Biotechnology from a “sell” rating to a “hold” rating in a research note on Saturday, August 8th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $21.86.

Trending Headlines about Vir Biotechnology

Here are the key news stories impacting Vir Biotechnology this week:

• Positive Sentiment: Vir reported a Q3 loss of $0.57 per share, better than analysts’ expected loss of roughly $0.75–$0.80 and the $1.17 loss a year earlier. The improving loss may support investor sentiment. Zacks Q3 results
• Neutral Sentiment: Management said it expects to report topline results from the ECLIPSE 1 hepatitis delta trial this quarter and highlighted additional oncology catalysts. These events could be important stock drivers, but their impact will depend on the data and updates. Vir corporate update and Q3 results
• Neutral Sentiment: An executive sold a small number of shares under a pre-arranged trading plan to cover tax withholding on vested equity awards. The stated reason and limited size make the transaction less informative as a signal about the company’s outlook. SEC filing
• Negative Sentiment: Revenue was negative $0.19 million, missing analysts’ estimate of $0.98 million and declining 178.3% year over year. The revenue shortfall tempers the earnings beat. MarketBeat Q3 results

About Vir Biotechnology

Vir Biotechnology, Inc is a clinical-stage immunology company focused on developing medicines to prevent and treat serious infectious diseases and other immune-related conditions. The company uses antibody engineering, immunologic approaches and other technologies to identify and advance therapies designed to harness or modify the immune system.

Vir’s research and development programs have included treatments and vaccines for hepatitis B, human immunodeficiency virus (HIV), influenza and other infectious diseases.